How Novartis Got Its Vaccines Groove Back, Intellikine Gets a Drug Development Deal, Ambrx CEO Departs, & More San Diego Life Sciences News
San Diego’s life sciences newsmakers must have been over compensating, after slacking off last week. This week we have deals, fundings, comings, and goings—not to mention Luke scoops No. 1 and 2—and our summary begins now.
—Infinity Pharmaceuticals of Cambridge, MA, could pay San Diego-based Intellikine as much as $488.5 million in various types of payments under a global drug development and commercialization deal revealed last week. As much as $450 million depends on whether Intellikine can win regulatory approval for two anti-cancer drug candidates and get them to the marketplace.
—UC San Diego Health Sciences and its Clinical and Translational Research Institute got a five-year, $37.2 million grant from the National Center for Research Resources (NCRR). The funding is intended to boost what’s known as “translational science,” which encompasses the concept of rapidly translating lab research into new and effective therapies.
—Luke scoop No. 1: Ambrx CEO Steve Kaldor, who joined the biotech startup three years ago, quietly left the company at the end of June. The company did not issue a statement about the executive departure, but a spokeswoman for Ambrx confirmed Kaldor was no longer with the company. The spokeswoman added that Peter Schultz, a renowned chemist, Ambrx founder, and a member of its board, is expected to offer more advice.
—Speaking of Peter Schultz, Luke also learned … Next Page »